R-Tech Ueno: Sucampo Pharmaceuticals, Inc. And Takeda Enter Into Global Licensing Agreement For AMITIZA® (Lubiprostone)
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573):
Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global license, development, commercialization and supply agreement for AMITIZA® (lubiprostone). (See Sucampo press release)
Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA® in all global markets, except Japan and the People’s Republic of China.
Help employers find you! Check out all the jobs and post your resume.
Sucampo Pharmaceuticals, Inc. (“Sucampo”) and Takeda Pharmaceutical Company Limited (Takeda) announced that on October 17, 2014, they have entered into a global license, development, commercialization and supply agreement for AMITIZA® (lubiprostone). (See Sucampo press release)
Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA® in all global markets, except Japan and the People’s Republic of China.
Help employers find you! Check out all the jobs and post your resume.